Kerendia

News

Bayer gets sought-after heart failure use for Kerendia

Bayer's Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's blockbuster sales prospects.

News

Bayer trial combines two top drugs for kidney disease

Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.

News

Bayer CEO confident firm can cope with Xarelto hit

Bayer's CEO says new product launches will offset the decline in sales of anticoagulant Xarelto over the course of 2025.

News

Kerendia pill bottle with tablets on surface

Bayer files finerenone in EU for heart failure

Bayer has filed its mineralocorticoid receptor antagonist finerenone as a treatment heart failure in the EU, but can it meet blockbuster sales hopes?

News

Kerendia works in heart failure, but how might it be used?

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but th

News

Bayer CEO says recovery on track as key drug products shine

Bayer has joined its peers among European drugmakers with a hike in pharma forecasts for the year, as it recorded a rise in group sales, but lower profits for the second quarter.

Bayer gets sought-after heart failure use for Kerendia

Bayer trial combines two top drugs for kidney disease

Bayer CEO confident firm can cope with Xarelto hit

Bayer files finerenone in EU for heart failure

Kerendia works in heart failure, but how might it be used?

Bayer CEO says recovery on track as key drug products shine

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Kerendia

Editor's Picks